A new prototype allows AA and NA sponsors to conduct anonymous daily check-ins with sponsees via pseudonymous threads, aiming to improve support while maintaining anonymity.
Anonymous daily check-ins for 12-step sponsors
Browsing Category
Healthcare operations
30 posts
THE STORK FOUNDATION FOR INFERTILITY OPENS 2026 GRANT APPLICATIONS TO EASE FINANCIAL BURDEN OF IVF TREATMENTS
The Stork Foundation for Infertility has announced the opening of its 2026 grant applications to help reduce the financial burden of IVF treatments.
Clearmind Medicine Successfully Completes Part A Of Its FDA Regulated Phase I/II Trial
Clearmind Medicine has successfully completed Part A of its FDA-regulated Phase I/II trial, advancing its research into novel therapies.
Advances In CRISPR Tech Boost Consumer Safety By Shredding Resistant Cancer Cells
New CRISPR technology has demonstrated the ability to selectively destroy resistant cancer cells, including ‘undruggable’ types, marking a significant step in cancer therapy.
TransMedics To Report Second Quarter 2026 Financial Results On August 4, 2026
TransMedics will release its second quarter 2026 financial results on August 4, 2026, with analysts and investors awaiting the report’s details on company performance.
MaxCyte® Announces Multi-Platform Technology License Partnership With Genentech® To Advance Cell Therapy Development
MaxCyte announces a multi-platform technology licensing partnership with Genentech to accelerate cell therapy development, expanding collaborative capabilities.
Neuronata-R Retains Conditional Approval In South Korea
South Korea’s regulatory agency retains conditional approval for Neuronata-R, a key development for its market access and future commercialization.
Daily Maternal Check-ins: Supporting Healing After Birth
A new pilot program tests daily postpartum check-ins for first-time mothers at home, aiming to improve recovery and reduce risks after birth.
4DMT Announces Positive 2-Year Data From PRISM Phase 2B Clinical Trial In A Broad Wet AMD Population
4DMT announced positive two-year data from its PRISM Phase 2b clinical trial in a broad wet AMD population, showing promising efficacy results.
Harmony Biosciences Holdings, Inc. Files 8-K: Executive Change
Harmony Biosciences announced an executive change through an SEC 8-K filing, signaling leadership updates at the company.
